Abstract: An air conditioning device for a vehicle includes: a housing having an inside divided into an inflow space, a heat exchange space, and an outflow space, which are straightly arranged, and having a plurality of discharge ports, which communicates with an interior, at the inflow space; a blowing unit disposed at the inflow space of the housing and configured to blow air; a heat exchange unit disposed at the heat exchange space of the housing and configured to adjust a temperature of conditioned air by exchanging heat with air; and an opening-closing door disposed at the outflow space of the housing and configured to open and close the plurality of discharge ports such that conditioned air at an adjusted temperature selectively flows to the plurality of discharge ports. The air conditioning device adjusts the temperature of conditioned air for respective modes and reduces a flow resistance of air.

Abstract: The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.

Abstract: The present invention relates to a biodegradable polymer microsphere-containing sustained-release injection containing escitalopram as an active ingredient, and to a method for manufacturing the same. In the case of escitalopram microspheres, there is a problem of low encapsulation rate, fracture due to weak strength, and initial over-release due to the phase separation of the liquid drug and the polymer inside the microspheres. In order to solve the problem, it is possible to maximize the encapsulation amount and the encapsulation efficiency of the escitalopram adding a hydrophobic solidifying agent to uniformize the non-uniform phase, to overcome the cracking of the microspheres at high loading conditions, and to properly control the initial release and release delay of the microspheres.

Abstract: Methods of fabricating semiconductor devices are provided. A method of fabricating a semiconductor device includes selecting a target pattern from a target design layout. The target pattern includes: a target net; a target via that is electrically connected to the target net; and a crossing net that is electrically connected to the target via on a different level from the target net. The method includes analyzing a peripheral pattern that is adjacent the target net. Moreover, the method includes generating a redundant net, and a redundant via that electrically connects the redundant net and the crossing net. Related layout design systems are also provided.

Abstract: The present invention relates to a biodegradable polymer microsphere-containing sustained-release injection containing escitalopram as an active ingredient, and to a method for manufacturing the same. In the case of escitalopram microspheres, there is a problem of low encapsulation rate, fracture due to weak strength, and initial over-release due to the phase separation of the liquid drug and the polymer inside the microspheres. In order to solve the problem, it is possible to maximize the encapsulation amount and the encapsulation efficiency of the escitalopram adding a hydrophobic solidifying agent to uniformize the non-uniform phase, to overcome the cracking of the microspheres at high loading conditions, and to properly control the initial release and release delay of the microspheres.

Abstract: Methods of fabricating semiconductor devices are provided. A method of fabricating a semiconductor device includes selecting a target pattern from a target design layout. The target pattern includes: a target net; a target via that is electrically connected to the target net; and a crossing net that is electrically connected to the target via on a different level from the target net. The method includes analyzing a peripheral pattern that is adjacent the target net. Moreover, the method includes generating a redundant net, and a redundant via that electrically connects the redundant net and the crossing net. Related layout design systems are also provided.

Abstract: The present invention relates to a pharmaceutical composition or an anticancer agent for preventing and treating non-small cell lung cancer, containing a substance for regulating the expression or activity of transmembrane 4 L six family member 4 (TM4SF4). More specifically, the present invention relates to a use of a substance for regulating the expression or activity of TM4SF4 as an anticancer drug or an anticancer agent with respect to non-small cell lung cancer, wherein it was ascertained that it is possible to decrease the growth, metastasis, and infiltration of adenocarcinoma cells and radioresistance by decreasing the expression of TM4SF4 in adenocarcinoma among non-small cell lung cancers and to decrease the growth, metastasis, and infiltration of the cells and radioresistance by increasing the expression of TM4SF4 in other non-small cell lung cancers except adenocarcinoma.

Abstract: The present invention relates to a pharmaceutical composition or an anticancer agent for preventing and treating non-small cell lung cancer, containing a substance for regulating the expression or activity of transmembrane 4 L six family member 4 (TM4SF4). More specifically, the present invention relates to a use of a substance for regulating the expression or activity of TM4SF4 as an anticancer drug or an anticancer agent with respect to non-small cell lung cancer, wherein it was ascertained that it is possible to decrease the growth, metastasis, and infiltration of adenocarcinoma cells and radioresistance by decreasing the expression of TM4SF4 in adenocarcinoma among non-small cell lung cancers and to decrease the growth, metastasis, and infiltration of the cells and radioresistance by increasing the expression of TM4SF4 in other non-small cell lung cancers except adenocarcinoma.

Abstract: The present invention relates to a radionuclide-chitosan complex solution and its preparation method, and more particularly to the radionuclide-chitosan complex solution having a viscosity of 300˜2,400 cps, comprising an aqueous chitosan solution or a freeze-dried chitosan labeled with a radionuclide. The radionuclide-chitosan complex solution according to the present invention has a stable gelation state at a target region when injected into the body while maintaining a labeling yield of radioisotope to chitosan above 99%. Side effects may be minimized and treatment efficiency may be increased when injected to a patient.

Abstract: The present invention relates to a method for preparing a radioactive film for local radioactive treatment. More particularly, the present invention relates to a method for preparing a radioactive film comprising the steps of; dissolving 0.1˜14.5 weight % of a stable nuclide and 13˜32.5 weight % of a film-forming base for the total amount of a solvent in the solvent; applying a stable nuclide solution on a release paper by a coater and drying; and irradiating a stable nuclide film with neutrons in a nuclear reactor. A method for preparing a radioactive film according to the present invention provides a radioactive film having a uniform distribution of radionuclides and an even thickness. Therefore, the therapeutic efficacy of the radioactive film for selective treatment of a lesion may be maximized by attaching the radioactive film on a patient's skin or a mucous membrane and by direct radioactive radiation.

Abstract: The present invention relates to a preparation method for technetium-antimony trisulfide nanocolloid, more precisely, a preparation method for technetium-antimony trisulfide nanocolloid which is characterized by the processes of mixing and stirring or irradiating of pertechnetate and antimony sulfide nanocolloid in the presence of borohydride exchange resin to obtain the technetium-antimony trisulfide nanocolloid radioactive complex.

Abstract: Disclosed is a composition for treating prostate cancer. The composition for treating prostate cancer comprises as an effective ingredient a radioisotope-chitosan complex that includes a therapeutic radioisotope emitting beta radiation and chitosan. Also, the present invention discloses a kit for preparing the composition. When directly administered to a prostate cancer tissue, the radioisotope- chitosan complex is deposited in the applied target site while not leaking from the applied target site, and strongly inhibits the growth of prostate cancer cells while minimizing the side effects of conventional therapies, including urinary incontinence, urethral stricture and rectal bleeding. In addition, the radioisotope-chitosan complex may be used as an effective therapeutic agent for hormone-independent prostate cancer that is resistant to hormone therapy.

Abstract: A method for labelling a sulfide compound with technetium or rhenium, comprising the reaction of a disulfide compound with pertechnetate or perrhenate in the presence of borohydride exchange resin to obtain a complex of technetium or rhenium with the sulfide compound. The method can directly label disulfide compounds with technetium or rhenium, can skip the synthetic step of thiol-protected S-precursor, and is useful for high value-added radiopharmaceuticals.

Abstract: The present invention relates to a method of preparing technetium or rhenium complex for radiopharmaceuticals, through reaction of pertechnetate or perrhenate with a ligand in the presence of a reducing agent, wherein the reducing agent is a borohydride exchange resin (BER). The borohydride exchange resin of the present invention has advantages of being stable in a wide range of Ph, including acidic or alkaline condition(Ph 2˜14) and thus being applicable to biological materials as well as being easily removable through filtration when being administrated. Also since the radiolabelled complex is produced under conditions milder than those required for the conventional reducing agents as well as has high radiochemical purity and high labeling efficiency, the conventional reducing agents can be replaced by the BER of the present invention.

Abstract: The present invention relates to a method of preparing technetium or rhenium complex for radiopharmaceuticals, through reaction of pertechnetate or perrhenate with a ligand in the presence of a reducing agent, wherein the reducing agent is a borohydride exchange resin (BER) . The borohydride exchange resin of the present invention has advantages of being stable in a wide range of Ph, including acidic or alkaline condition(Ph 2˜14) and thus being applicable to biological materials as well as being easily removable through filtration when being administrated. Also since the radiolabelled complex is produced under conditions milder than those required for the conventional reducing agents as well as has high radiochemical purity and high labeling efficiency, the conventional reducing agents can be replaced by the BER of the present invention.

Abstract: The present invention relates to a method for labelling a sulfide compound with technetium or rhenium, comprising the reaction of a disulfide compound with pertechnetate or perrhenate in the presence of borohydride exchange resin to obtain a complex of technetium or rhenium with the sulfide compound. The method can directly label disulfide compounds with technetium or rhenium, can skip the synthetic step of thiol-protected S-precursor, and is useful for high value-added radiopharmaceuticals.

Abstract: The present invention relates to novel antibacterial agents wherein the lone pair electrons of nitrogen atoms of amine compounds with high boiling point or water-soluble polymer with basic nitrogen at the backbone or side chain are coordinated with silver ion, and antibacterial and deodorizing solution comprising them. Since the antibacterial agents of the present invention has silver (Ag) ion coordinated with the lone pair electrons of nitrogen atom, the problems of conventional silver (Ag) compounds, i.e., their ease discoloration in general waters such as tap water and industrial water, are solved, and the inherent antibacterial activity is maintained due to the stabilization of silver ion (Ag+). Also, since they are highly soluble in water, they can be prepared in liquid form to be used for antibacterial and deodorizing purposes.

Abstract: Electron beam irradiation step is followed by alkaline material atomizing step in the present invention. Since irradiation step and alkaline material atomizing step is conducted in different time and in different reactors, the construction cost of X-ray shielding concrete is decreased remarkably. If the humidity of incinerator effluent gas is more than 100 g/Nm.sup.3 in dry basis by adding a steam of 110.degree..about.200.degree. C., harmful substances are efficiently removed by electron beam irradiation. As a result, it is possible to realize a space-saving equipment, a reduction of required energy, a simple operation controlling, and a prevention of occurrence of secondary environment pollution.